The drugmaker’s move to seek FDA approval comes after positive results from a phase 3 trial, which found the therapy was able to demonstrate significant improvement in patients’ conditions, according to a May 30 news release.
While rare, pulmonary arterial hypertension is a serious condition that causes high blood pressure in the arteries of the lungs. In clinical trials, the tablet, known as Opsumit, lowered patients’ risk of hospitalization due to the condition and slowed the progression of the disease.
Should the FDA grant approval of the drug, it “has the potential to cover all guidelines and recommended treatment pathways,” the release states.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
